PPAR activity regulators

Details PPAR activity regulators PPAR activity regulators

2007-05-25

2010-06-01

Kumar, Shailendra (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Fatty compounds having an acid moiety which contains the...

C554S035000, C514S563000

Reexamination Certificate

active

07728158

ABSTRACT:
The object of the present invention is to provide PPAR (peroxisome proliferator-activated receptor) activity regulators, which can be widely used for improving insulin resistance and preventing/treating various diseases such as diabetes, metabolic syndromes, hyperlipemia, high-blood pressure, vascular disorders, inflammation, hepatitis, fatty liver, liver fibrosis, NASH (non-alcoholic steatohepatitis) and obesity.The present invention provides PPAR activity regulators which comprise an acylamide compound having the specific structure, prodrugs thereof, or pharmaceutically acceptable salts thereof.

REFERENCES:
patent: 6090250 (2000-07-01), Mazzeo et al.
http://en.wikipedia.org/wiki/Prodrug (2 pages).
Han et al. et al., Targeted Prodrug Design to Optimize Druge Delivery, 2000, AAPS pharmsci, vol. 2, (1), article 6, pp. 1-11.
http://en/ikipedia.org./siki/Levopoda(5 pages).
Delerive et al., Peroxisome proliferator-activated receptors in inflammation control, 2001, (Journal of Endocrinology, vol. 169, pp. 453-459).
Grunell et al. , The Metabolic Syndrome: Peroxisome Proliferator-activated Receptor gamma and its Therapeutic Modulation, 2003, Journal of Clinical Endocrinology & Metabolism, 88(6), pp. 2412-2421.
Jiang et al., Lingands of Peroxisome Proliferator-activated Receptro Inhibit Homocysteine-induced DNA Methylation of Inducible Nitric Oxide Synthase Gene, 2007, Acta Biochemica et Biophysica Sinica, 39(5), pp. 366-376.
Rakic et al., Peroxisome Proliferator-Activated Receptro alpha Antagonism Inhibits Hepatitis C Virus Replication, 2006, Chemistry & Biology, 13, pp. 23-30).
Williams et al., Peroxisome proliferator-Activated Receptro-alpha, Activation Reduces Salt-Dependent Hypertension dur9ign Chronic Endothelin B Receptor Blockade, Aug. 2005 Hypertension, pp. 366-371.
Zhao et al., Peroxisome proliferator activated receptro-gama in pathogenesis of experimental fatty liver disease, 2004, World Journal of Gastroenterology, 10(9), pp. 1329-1332.
Evan, R. M., et al., “PPARs and the Complex Journey to Obesity,” Nature Medicine, vol. 10, No. 4, Apr. 2004, pp. 1-7.
Henke, B. R., “Peroxisome Proliferator-Activated Receptor α/γ Dual Agonists for the Treatment of Type 2 Diabetes,” J. Med. Chem., 47, 2004, pp. 4118-4127.
Skrumsager, B. K., et al., “Ragaglitazar: The Pharmacokinetics, Pharmacodynamics, and Tolerability of a Novel Dual PPAR α and γ Agonist in Healthy Subjects and Patients with Type 2 Diabetes,” J. Clin. Pharmacol., 43, 2003, pp. 1244-1256.

Affiliated with

Also associated with

Rating

PPAR activity regulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with PPAR activity regulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PPAR activity regulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4242086